ELISA Substrates and Reagents Market Size, Share, and Industry Analysis, By Product Type (Substrates {Chromogenic HRP, Alkaline Phosphatase (AP), Chemiluminescent HRP and Others} and, Reagents {Blocking Buffer, Wash Buffer, Stop Reagents, Detection Reagents, and Others}), By Application (Molecular Biology Research, Drug Discovery, Diagnostics, and Others), By End User (Pharmaceutical and, Biotechnology Companies, Research and Academic Institutes, Diagnostics Centers, and Others), and Regional Forecast, 2026-2034

The global ELISA substrates and reagents market is projected to grow on an upward trajectory in the forthcoming years due to the increasing applications of ELISA for diagnostic purposes, biomarker detection in oncology and cardiovascular research, and in immunogenicity and potency assays in biotechnology research. ELISA assays are used to detect antibodies in a sample in response to pathogen exposure or vaccination. Such factors drive the increasing use of ELISA for tests to detect various infectious diseases such as influenza, HIV, dengue fever, and Lyme disease. 

ELISA is used in many applications, including screening serum antibody concentrations, drug screening, and allergen testing. Such wide application leads to increasing use of ELISA kits. This leads to a heightened demand for substrates and reagents used in the assay. Such factors are expected to fuel the growth of the global ELISA substrates and reagents market. Furthermore, strategic collaborations of key companies operating in the market to offer new and more sensitive reagents for more precise results are expected to propel the growth of the market in the forthcoming years.

• For instance, in February 2024, Agdia, Inc. launched the commercial release of TMB Peroxidase Substrate, a critical visualization reagent used in ELISA for diagnostic applications.

ELISA Substrates and Reagents Market Driver

Emphasis on Shift toward More Sensitive Substrates Offering a Dynamic and Precise Range to Drive Market Growth

The current substrates utilized in the ELISA assays require reaction termination with acid and showcase limited sensitivity to many antibodies. A shift toward more sensitive substrates, such as chemiluminescent (luminol-based) and fluorogenic substrates, enables higher sensitivity, broader dynamic range, and faster signal statistics. The heightened sensitivity expands the application areas for these ELISA substrates and drives the market growth.

Additionally, numerous product launches by key companies are expected to support the growth of the market further.

• For instance, in October 2022, Neogen Corporation added chemiluminescent substrate to the trusted K-Blue product line. The substrate offers high sensitivity. This horseradish peroxidase substrate is intended for microwell and ELISA applications and demonstrates excellent long-term stability.

Comparative Study Analyzing Total agreements of In-house ELISA and two commercially available serological assays in Ethiopia (%)

In April 2025, an article was published titled ‘Comparative evaluation of in-house ELISA and two commercial serological assays for the detection of antibodies against SARS-CoV-2’ that compared the performance of in-house ELISA with two established serological assays, Elecsys CLIA and Rapid LFA test for SARS-CoV-2 antibody detection in Oromia region, Ethiopia. It reported that the percentage agreement between the Elecsys CLIA and in-house ELISA was relatively high at 80.8%, indicating significant diagnostic accuracy. In contrast, the percentage agreement between the in-house ELISA and the Rapid LFA test (IgG only) was 0.52, highlighting moderate variability in diagnostic accuracy.

ELISA Substrates and Reagents Market Restraint

Emergence of Alternative Technologies to Hamper Demand for ELISA Substrates and Reagents

Emergence of alternative technologies such as Luminex xMAP or MSD electrochemiluminescence (ECL), allowing simultaneous measurement of multiple antibodies at a time, may adversely impact the growth potential of the market. These alternative tools require far less sample volume and can analyse several antibodies simultaneously. Such factors limit the demand for ELISA substrates and reagents, hampering market growth. Molecular diagnostic tools such as PCR, qPCR, and next-generation sequencing are increasingly being relied heavily than ELISA for infectious disease detection and genetic profiling. These platforms often provide faster turnaround and higher sensitivity, further limiting the growth of traditional ELISA reagents. 

ELISA Substrates and Reagents Market Opportunity

Emergence of Portable ELISA Kit and Compact Readers to Boost Product Adoption and Offer Growth Opportunity

The growing availability of portable ELISA kits and compact readers is creating significant opportunities for market expansion. These solutions address the demand for decentralized and point-of-care diagnostics, enabling accurate and rapid testing outside of traditional laboratory environments. By improving accessibility and ease of use, portable ELISA platforms are expected to drive adoption in both developed and resource-constrained regions. This shift opens new avenues for substrate and reagent providers to supply stable, ready-to-use formulations tailored for portable applications, ultimately broadening their customer base and reinforcing ELISA’s role as a trusted diagnostic tool.

Additionally, the global market is witnessing heightened research and development, leading to novel product launches in the area to provide valuable tools for biocatalysis applications.

• For instance, in November 2020, Enzo Biochem launched a portable microplate reader for use with immunoassays such as ELISA. The company provided more than 17,000 enzyme-linked immunosorbent assay (ELISA) and other assay kits to deliver precise and accurate results. Such developments are expected to open new avenues for growth.

Key Insights

The report covers the following key insights:

• Overview: Applications of ELISA Substrates and Reagents
• Comparative Analysis of Portable vs. Laboratory ELISA Usage
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• New Product Launches, By Key Companies

Segmentation

Analysis by Type

By product type, the market is divided into substrates {Chromogenic HRP, Alkaline Phosphatase (AP), Chemiluminescent HRP and Others} and, reagents {blocking buffer, wash buffer, stop reagents, detection reagents, and others}.

The reagents segment is expected to dominate the global ELISA substrates and reagents market. Reagents are used in large quantities for the ELISA kits. High usage of reagents is expected to drive the growth of the segment. Also, due to the high importance of reagents, many key players focused on launching reagent kits, further supporting the market growth. 

• For instance, in February 2025, Gyros Protein Technologies AB launched two reagent kits, namely Gyrolab HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. These were developed in collaboration with BioGenes GmbH. These kits facilitate the detection of host cell proteins (HCPs) in medicines made from HEK293 cells that are used in drug development. 

Analysis by Application

By application, the market is divided into molecular biology research, drug discovery, diagnostics, and others.

The molecular biology research segment is projected to hold a considerable market share of the global market in 2024. The ELISA assays are performed to test the impurities and evaluate the manufacturing process of therapeutics. These wide applications of the ELISA assay in research are driving the growth in the segment. 

• For instance, in January 2024, Rockland launched an impurity detection ELISA kit for accurate measurement of nucleases across a spectrum of therapeutic manufacturing methods. The Accusignal nuclease ELISA kit serratia marcescens endonuclease, such as benzonase, denarase, and turbonuclease, to evaluate manufacturing processes for biological therapeutics, gene therapy vectors, vaccine preparations, and more.

 Analysis by End User 

By end user, the market is divided into pharmaceutical and biotechnology companies, research and academic institutes, diagnostics centers, and others.

The pharmaceutical and biotech companies are expected to account for a major share of the global market. Increasing use of ELISA kits to evaluate the manufacturing efficiency and monitor operational efficiency, along with the detection of impurities in biopharmaceutical samples, is expected to drive the market growth. Furthermore, established players are engaging in strategic product launches to expand their product offerings in the market.

• For instance, in May 2024, Creative Diagnostics launched new, highly sensitive and specific T7 RNA Polymerase ELISA Kits for the detection and quantitative determination of T7 RNA Polymerase in biopharmaceutical samples. These kits provided a critical tool for researchers and manufacturers to monitor and control process-related impurities, ensuring the safety and efficacy of biologic drug products—such developments are expected to drive the segmental growth in the market.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global ELISA substrates and reagents market. The share of the region is attributed to numerous factors such as biopharmaceutical R&D, high healthcare spending, and rapid adoption of advanced diagnostic technologies. Such factors drive the growth in the region. Furthermore, key industry players are redirecting their resources toward new product development to cater to the increasing demand of the market.

• For instance, in February 2023, Charles River Laboratories International, Inc. launched its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantification of residual host cell proteins (HCP) in CHO-based biotherapeutics. Such developments are expected to expand the application horizon and grow the enzymes and inhibitors market in the forthcoming years.

Europe is expected to hold a substantial global market share. The robust research and development infrastructure, along with a well-established biotechnology sector, driving advanced assay adoption, and strategic collaborations among academic institutes, are some factors supporting growth in the region. Also, strategic collaboration among key players is needed to boost the market growth. 

• For instance, in May 2024, Life Science Group collaborated with Somnus Scientific and Creonate Manufacturing to develop a laboratory test (ELISA) measuring propofol levels into a rapid point-of-care test in the U.K. Such developments to driving the growth in Europe.

Asia Pacific is expected to grow with a significant CAGR during the forecast period. The increasing prevalence of infectious diseases is expected to heighten the demand for precise diagnostic tools such as ELISA, which in turn, augments the ELISA reagents and substrates product adoption. Additionally, increasing government investments and new product launches are projected to drive the growth of the market in the region.

• For instance, in May 2020, Medical and Biological Laboratories Co., Ltd. (MBL), launched an ELISA-based Companion Diagnostic Kit for Spinal Muscular Atrophy (SMA). The MEBCDX AAV9 test kit will enable laboratory testing in Japan. Such developments are expected to drive the regional growth in the market.

Key Players Covered

The global ELISA substrates and reagents market is fragmented with the presence of several companies of various sizes.

The report includes the profiles of the following key players:

• Creative Enzymes. (New York, U.S.)
• Thermo Fisher Scientific Inc. (Waltham, U.S.) 
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• Abcam Limited. (U.K.)
• LGC Clinical Diagnostics, Inc. (U.K.)
• Vector Laboratories, Inc. (U.S.)

Key Industry Developments

• In December 2024, Panadea Diagnostics launched advanced ELISA Kits for Flavivirus Detection of Zika virus, Dengue virus, and West-Nile virus, along with a further IgM detection kit for Dengue virus. These kits were highly sensitive to IgG and IgM detection with high base specificity and targeted cross-reactivity elimination.
• In June 2021, J Mitra and Company launched the COVID-19 Microlisa ELISA Test kit. The test kit brought down the overall cost of testing.